BayONE Scientific (Guangdong Yiwan Life Sciences) — company site

Note: this is a lightly condensed English translation of the company’s Chinese-language website (bayonesci.com, homepage + About page). Original language: Chinese.

BayONE Scientific — “AI-driven brain science and neurological disease R&D acceleration platform”. Founded 2020 (Guangdong Yiwan Life Technology Co., Ltd.); headquartered on Guangzhou International Bio Island.

Positioning and platform

• Combines AI with experimental-animal technologies: proprietary intelligent instruments + data platforms for brain research and CNS drug discovery.
• Five-step pipeline: smart cage (input) -> multimodal heterogeneous data capture -> multimodal deep learning -> biological insight extraction -> R&D decision tree.
• Core technology: BehaviorAtlas 3D-AI behaviour analysis (core method published in a Nature sub-journal, 2021); software suite includes 3D-AI Mouse Behavior Capture, 3D-AI Non-human Primate Behavior Capture, motor-function, eye-tracking (freely-moving and head-fixed), VR control, face analysis, scratch analysis, optomotor, realtime analysis, and Pose Labeler modules (software copyright registrations); hardware IP covers behaviour-recognition apparatus, 3D motion-capture devices, state-and-graph behaviour quantification, head-fixation and running-ball devices.
• Cloud/AI: EthoAI animal-behaviour analysis cloud platform; EthoAgent large-model agent.
• Forthcoming (2026 milestones): HCM “smart furniture” home cage; fully automated eight-paradigm fine-motor behaviour assessment system.

Company facts (company-reported)

• Founded 2020 in Shenzhen; Guangzhou headquarters, Shenzhen animal centre (2,100 m2 SPF barrier facility, 10,000+ rodent cage positions; CRO services), Jiaxing manufacturing subsidiary.
• Team 80+ interdisciplinary (5 PhDs); 50+ IP items (patents + software copyrights).
• Financials: several tens of millions of RMB raised cumulatively, including an A round (2024) of several tens of millions RMB; national high-tech enterprise; Guangdong provincial key R&D programmes.
• Scale: products deployed in 200+ research laboratories; 50+ user publications; winner of the 14th China Innovation and Entrepreneurship Competition (Guangzhou, medicine track, 2026); selected as an MIIT (Ministry of Industry and Information Technology) AI application typical case (2026).
• Selected collaborations: automated fine-motor assessment systems for mice/rats with the CAS Institute of Neuroscience (Shanghai); NHP drug-efficacy screening with a Shanghai primate CRO; two-photon + behaviour combined recording with a third partner; partnership with Pfizer (2026).
• Confidence note: company-reported figures (funding, lab counts) not independently verified.